- AMLX -1.12%
Analysts Just Slashed Their Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) EPS Numbers
Yahoo Finance · 3 weeks ago
Open | 1.7900 |
High | 1.8400 |
Low | 1.7000 |
Mkt Cap | 119.69M |
P/E (TTM) | 2.51 |
Div & Yield | N/A & N/A |
Prev. Close | 1.7800 |
52 Wk. Low | 1.7000 |
52 Wk. High | 30.5000 |
Related stocks
American biopharmaceutical company
Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis. Wikipedia
(USD) | Q4 2023 | Y/Y |
---|---|---|
Revenue | 108.45M | 395.50% ▲ |
Net Income | 4.73M | - |
Diluted EPS | 0.07 | - |
Quarter | EPS Estimate | EPS Actual |
---|---|---|
Q1 2024 | -$0.01 | - |
Q4 2023 | $0.23 | $0.07 |
Q3 2023 | $0.43 | $0.30 |
S&P 500^GSPC | 5,099.96+51.54 (+1.02%) |
Dow 30^DJI | 38,239.66+153.86 (+0.40%) |
Nasdaq^IXIC | 15,927.90+316.14 (+2.03%) |
Bitcoin USDBTC-USD | 62,881.22-2.47% |
7.87+3.69% | |
7.35+43.84% |